echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The University of Hong Kong and Xiamen University Science sub-journals co-published a paper: a novel coronavirus recombinant protein vaccine

    The University of Hong Kong and Xiamen University Science sub-journals co-published a paper: a novel coronavirus recombinant protein vaccine

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, the team of Professor Xia Ningshao from Xiamen University published a report entitled “A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV- 2 infection and transmission in hamsters" research paper
    The research has developed a new coronavirus recombinant protein vaccine based on recombinant spike protein and innovative adjuvants.
    The immunogenicity and effectiveness of the vaccine have been verified in a variety of animal models, providing a basis for the prevention and control of the new coronary pneumonia epidemic.
    A new candidate vaccine


    The coronavirus pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is changing the pattern of global public health
    So far, 218 countries and regions around the world have confirmed SARS-CoV-2 infection, with more than 188 million confirmed COVID-19 cases and more than 4 million deaths

    A safe and effective new coronavirus vaccine is an important means to control the epidemic of the new coronavirus


    At present, a variety of vaccines have been marketed or used in emergency around the world.
    Clinical trials and real-world research data have proved that vaccination with the new crown vaccine can effectively reduce the risk of viral infection and reduce the severity of the disease

    However, whether or not individuals can obtain sterilizing immunity against the new coronavirus through strong vaccine immunization, thereby effectively suppressing the risk of virus transmission, remains to be further studied and clarified


    In this study, the researchers designed a novel coronavirus recombinant protein vaccine StriFK-FH002C based on the immunogen StriFK of the SARS-CoV-2 recombinant spike protein expressed in CHO cells and the innovative adjuvant FH002C
    The vaccine induces high titers of neutralizing antibodies in mice, hamsters and cynomolgus monkeys, which is 30 to 250 times higher than the neutralizing antibodies of human COVID-19 convalescent plasma.
    It is in terms of the speed and strength of neutralizing antibodies.
    Both have significant advantages over traditional aluminum adjuvant vaccines

    At the same time, the StriFK-FH002C vaccine can induce a strong cellular immune response in mice, overcoming the weakness of traditional aluminum adjuvants in inducing cellular immune responses


    In the protective test, the researchers used the hamster animal model that simulates severe new coronary pneumonia in humans, using two modes of direct challenge and close transmission to prove that StriFK-FH002C immunity can give hamsters good protection against the new coronavirus.
    Effect: Significantly reduce the viral load of respiratory tract tissues such as turbinates, trachea, lungs, etc.
    , so as to prevent the test animals from lung tissue lesions caused by the new crown infection


    More importantly, the study used an air transmission test to show that StriFK-FH002C vaccination can not only protect the vaccinated animals, but also effectively reduce the risk of virus transmission from vaccinated individuals to unvaccinated individuals and cause disease
    By comparing and analyzing the changes in antibody response before and after the challenge, studies have confirmed that in at least some animals, StriFK-FH002C vaccine immunization can confer sterilizing immunity against the new coronavirus (sterilizing immunity)


    Doctoral student Wu Yangtao, doctoral student Huang Xiaofen, postdoctoral fellow Yuan Lunzhi, postdoctoral fellow Wang Shaojuan, postdoctoral fellow Zhang Yali and doctoral student Xiong Hualong are the co-first authors of the paper
    Professor Xia Ningshao, Professor Yuan Quan, Professor Zhao Qinjian, Assistant Professor Zhang Tianying, Professor Zhang Jun, Professor Guan Yi and Associate Professor Zhu Huachen of the University of Hong Kong are the co-corresponding authors of the paper

    The research was funded by the National Natural Science Foundation of China, the National Key Research and Development Program, the Guangdong-Hong Kong-Macao Joint Laboratory Fund, the Fujian Outstanding Youth Natural Science Foundation, and the Bill and Melinda Gates Foundation


    Paper link:



    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.